OrienX010

AXP000077.1 · Oncolytic virus

Platform
HSV-1 (ICP34.5- ICP47- ICP6-interrupted)
Originator
OrienGene Biotechnology
Sponsor
OrienGene Biotechnology

Names

NameTypeSource
OrienX010preferred name, codecurator, ncit

Virus

Role
Oncolytic
Family
Orthoherpesviridae
Virus
herpes simplex virus 1 (NCBI Taxonomy 10298)
Strain
clinical isolate (Chinese Han patient)
Replication
conditionally replicating
Modifications
ICP34.5 and ICP47 deleted; ICP6 interrupted
Transgenes
CSF2
Route
intratumoral
Source
evidence

Cross-references

NCI Thesaurus
C111893

Approvals

No regulatory approval recorded.

Clinical trials (5)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT04197882Clinical Study to Evaluate OrienX010 in Combination With Toripalimab as Neoadjuvant Treatment in Advanced MelanomaUnknownPhase 12019-05-272021-05-2733Melanoma
NCT04206358Study to Evaluate OrienX010 in Combination With JS001 in the Treatment of Stage IV (M1c) Liver Metastasis From MelanomaUnknownPhase 12019-05-132021-02-2730Melanoma
NCT04200040A Clinical Study to Evaluate the Safety and Efficacy of OrienX010 in Unresectable Malignant Melanoma PatientsUnknownPhase 22017-08-272022-12-27165Melanoma (Skin)
NCT03048253A Phase I-c Study of Recombinant GM-CSF Herpes Simplex Virus to TreatⅣ M1cUnknown2016-03-292017-10-1030Melanoma
NCT01935453A Phase I Study of Recombinant hGM-CSF Herpes Simplex Virus to Treat CancerCompletedPhase 12012-052014-0518Liver Cancer; Lung Cancer; Melanoma; Pancreatic Cancer

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 42226303Long-term survival benefit of neoadjuvant oncolytic virus plus PD-1 blockade in acral melanoma: implications of STING in resistance and potential therapy.Experimental hematology & oncology2026cited by trial NCT04197882
PMID 39572525Neoadjuvant oncolytic virus orienx010 and toripalimab in resectable acral melanoma: a phase Ib trial.Signal transduction and targeted therapy2024cited by trial NCT04197882
PMID 35383116OrienX010, an oncolytic virus, in patients with unresectable stage IIIC-IV melanoma: a phase Ib study.Journal for immunotherapy of cancer2022name in title: OrienX010

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 34277838Current status of intralesional agents in treatment of malignant melanoma.Annals of translational medicine2021name in abstract: OrienX010
PMID 29284308Fighting Cancer with Viruses: Oncolytic Virus Therapy in China.Human gene therapy2018name in abstract: OrienX010
PMID 28507788Adaptive T cell responses induced by oncolytic Herpes Simplex Virus-granulocyte macrophage-colony-stimulating factor therapy expanded by dendritic cell and cytokine-induced killer cell adoptive therapy.Oncoimmunology2017name in abstract: OrienX010

Notes

Chinese oncolytic HSV-1 armed with GM-CSF, built on a clinical isolate from a Han Chinese patient. Phase Ib in unresectable stage IIIC-IV melanoma published in J Immunother Cancer 2022.

How to cite

OrienX010 (AXP000077.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000077.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.